Despite claim and if successful, vaccine would take over a year to develop. It will target the virus’s Receptor Binding Motif (RBM), a critical weak point.
Gershoni, who has studied the family of viruses for 15 years, said that he was recently granted a patent by the United States Patent and Trademark Office for his vaccine design. He explained that the vaccine intends to target the virus’s Receptor Binding Motif (RBM), a critical weak point which allows the virus to attach itself and infect a target cell.
Once this protein binds to the cell receptor of a human cell, the viral membrane fuses with that of the human cell, which allows the genome, or genetic blueprint of the virus to enter human cells and begin infection.